#USA #Chicago #Liquid Biopsy #CNS Cancer #Belay Summit

Overview of the Belay Summit Study

A groundbreaking study published in the journal Cancers, by UT Southwestern Medical Center, has unveiled the impressive efficacy of the Belay Summit cerebrospinal fluid (CSF)-based liquid biopsy test. This innovative diagnostic tool has been demonstrated to inform clinical decisions in a remarkable 93% of cases involving suspected or confirmed central nervous system (CNS) cancers. Notably, this includes instances where standard cytology results have returned negative.

Study Details

The comprehensive study was conducted with a cohort of 120 patients, leading to an analysis of 123 specimen samples. The primary focus was on patients already under suspicion or confirmed to have CNS cancers. Surprisingly, standard CSF cytology reported negative results in 86% of the samples processed. In stark contrast, the Summit test yielded significant results, informing diagnosis, treatment choices, and even confirming the absence of malignancy in 93% of these cases.

Enhanced Sensitivity and Utility

One of the notable achievements of the Balay Summit test was its ability to detect clinically significant variants in more than half (56%) of the cytology-negative CNS cancer cases. Furthermore, it identified variants in all cases deemed positive by cytology, thereby demonstrating superior sensitivity. Where traditional cytology might fail, Summit provides crucial molecular characterization that is essential for guiding treatment selection and response assessments.

In addition to its sensitivity, the Summit test’s positivity was consistently reliable, remaining unaffected by corticosteroid use—a known confounding factor in cytological analyses.

Tracking Leptomeningeal Disease

The Summit platform also boasts unique capabilities in measuring quantitative variant allele frequency (VAF). This feature provides additional molecular insights beyond standard cytology. The study found that all specimens with VAF exceeding 5% correlated with confirmed cases of leptomeningeal disease (LMD), thereby illustrating the test's potential in refining diagnosis and monitoring of complex cases, which included two instances initially misclassified as parenchymal brain metastases.

The integration of serial testing among patients showed that declining VAF values were associated with clinical improvement, while stable VAF indicated a lack of treatment response—highlighting the test's role in dynamic monitoring of disease evolution.

Clinical Implications

Dr. Michael Youssef, a neuro-oncologist and the study's lead author, emphasized the importance of this research, stating, "This study documents what we observed across more than 120 patients at UT Southwestern. Summit informed clinical decisions in 93% of cases, including in patients with negative cytological results. For leptomeningeal disease, VAF measurements afford us quantitative support for diagnosis and long-term disease assessment that surpasses standard cytology and imaging assessments."

Since the initiation of the study, Belay Diagnostics has introduced Summit™ 2.0, an enhanced version now analyzing 520 genes for single nucleotide variations (SNVs) and insertions/deletions (indels), among others. Summit™ 2.0 boasts a clinical sensitivity of 96% and specificity of 98% specifically for CNS malignancies.

Belay Diagnostics, headquartered in Chicago, is committed to providing advanced diagnostic solutions for patients and healthcare professionals by utilizing over a decade of research from Johns Hopkins University. They have developed three proprietary CSF liquid biopsy tests—Belay Summit™ 2.0, along with Belay Ascent™ and Belay Vantage™—each designed to yield comprehensive molecular insights via a routine lumbar puncture, eliminating the need for invasive tissue biopsies.

For further exploration and access to the full study, please visit Belay Diagnostics.